Connect with us

China Manufactures COVID-19 Vaccine — Promising To Be Potent

Ghana News

China Manufactures COVID-19 Vaccine — Promising To Be Potent

Listen To The Audio

From afar, 2020 looked very promising in all aspects from 2019 until it really met us. In fact, the Novel Coronavirus has really made life unbearable for many across the globe. One thing the world is waiting for is a remedy to salvage the COVID-19 menace.

Most countries have strived to seek medical breakthroughs for this Coronavirus issue and success seems to be hovering around in the air.

Now the first vaccine candidate from China has completed its phase-1 trial on humans, and the results have been put online for everyone’s perusal.

The Lancet, a respected medical journal in the UK, published the results on Friday saying it is “safe” and “induces a rapid immune response.”

The journal published:

The research injected the potential vaccine into 108 volunteers. They were divided into three groups, each taking a different dose of the vaccine. The vaccine, classified as “recombinant adenovirus type-5 vectored” (Ad5-nCoV), acts as a natural infection and is especially good at teaching the immune system how to fight the virus.

During the next 28 days, no serious reactions were found, meaning the vaccine seemed to be tolerable by humans.

Also, antibodies against the SARS-CoV-2 started to surge two weeks after the injection and reached its peak on day 28.

The vaccine “warrants further investigation,” the paper on The Lancet concluded. A phase-2 clinical trial has started with 508 volunteers involved.

Continue Reading
Christopher Asante

C. A. Asante is a teacher by profession who has reported on a number of elections in Ghana for Central Press Newspaper. He is known among his peers as a researcher and regular contributor in Education, Politics, etc. Follow : Instagram- @ chris_asante1...Facebook: Asante Christopher Augustine...


More in Ghana News

Video Of The Week

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive latest and breaking news into your email.

Join 6,229 other subscribers

Trending News

To Top